Agenda. Genesys Capital Partners. The Opportunity. Our Approach

Transcription

1 MEDT Dinner Presentation September 28, 2005

2 Agenda Genesys Capital Partners The Opportunity Our Approach

3 Genesys Capital Partners

4 Genesys Capital Partners Successful Track Record Management experience and expertise Life Sciences focus Access to high quality proprietary deal flow

5 Active Start-Up and Seed Financier Start-Up and Seed Financings* of Canadian Life Sciences Companies GeneChem Ventures West Vengrowth RBC MDS T 2 C 2 BDC Source: Mary Macdonald & Associates * Start-Up and Seed Financings over $500,000

6 Fund I Performance (Vintage 2001)* Fund-raising Raised over $125 million Capital Deployment Invested over $75 million in 18 companies Deal Flow Founding or Initial Investor in 11 companies Strong Early Returns * March 1, 2001 August 31, 2005

7 Genesys Overview Founded in 2000 Raised over $125M in venture capital Canadian Life Sciences focus Successful Track Record Most active early-stage biotechnology investor in Canada

8 Genesys Team Kelly Holman, BSc, MBA Co-founder and Managing Director Ex-MDS Capital; Researcher at University of Toronto (genomics) Damian Lamb, MSc, MBA Co-founder and Managing Director Ex-MDS Capital; Researcher at McMaster (protein engineering) Judy Blumstock, BSc, MBA Venture Partner Ex-RBC Capital Partners; Drug Royalty Corp. Jamie Stiff, BSc, MBA Principal Researcher at SLRI/University of Toronto Kent Plumley, BSc, LLB Co-founder and Chair 35+ yrs in VC; Mitel and Newbridge; Senior Partner, Osler, Hoskin and Harcourt

9 The Opportunity

10 Healthcare Market: $3 Trillion and Growing Rapidly Growth Drivers: Aging population New science/ technologies Need to control healthcare costs Data explosion from Human Genome Project

11 Rapidly Expanding U.S. Biotech Sector Revenues $B $60B 18% CAGR $8B

12 The Canadian Opportunity

13 Canada Has The Science and Technology Canada has a comparative advantage in many areas of science and technology Highly educated workforce Legacy of scientific invention and innovation Government support and funding of basic R&D R&D cost advantages Montreal, Toronto, Vancouver and Ottawa large and emerging medical communities in North America

14 Top Research Institutes Are In Canada University of Washington Harvard University University of Pennsylvania University of Michigan - Ann Arbor John Hopkins University University of Toronto University of California - Los Angeles University of California - San Francisco Washington University in St. Louis Stanford University Yale University Duke University Columbia University University of Alberta Cornell University Baylor College University of British Columbia McGill University Number of Search Results from PubMed* (*Search limited to MEDLINE and 5 years)

15 Areas of Canadian Research Strengths Genetic Research Protein Research Stem Cell Biology Biomaterials Biomedical Engineering Tissue Transplantation Cardiovascular Disease Oncology Vaccine Development

16 The Challenge: Translating Science into Commercial Success Canadian Technology Commercial Success $ Pre Clinical Bridging the gap Clinical Market

17 Canada has had commercial success BIOCHEM PHARMA BIOCHEM PHARMA

18 however significant challenges remain Management Shallow pool of experienced management Few teams with successful track record(s) Investors underwriting the learning curve Capital Early-stage companies are poorly capitalized A handful of Canadian-based investors Depth of total Canadian-based pool of capital No consistent funding from deeper, international VC pools

19 The Commercial Opportunity is Clear Number of biotech companies with market cap >$1B 94 3 Canada U.S.

20 Capturing the Opportunity

21

22 Genesys Portfolio Target Areas Technology Platforms Biopharmaceutical Products Combination Products Cell Therapy Healthcare IT Medical Devices Seed Early Late Public

23 Recent Financing Activity

24 Recent M&A Activity Acquired By To Be Acquired By (?)

25 Q & A

26 MEDT Dinner Presentation September 28, 2005